Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$505.16 USD
-6.10 (-1.19%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $505.17 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
Price, Consensus and EPS Surprise
ELV 505.16 -6.10(-1.19%)
Will ELV be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ELV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ELV
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
ELV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elevance Health Stock Has More to Offer: Should You Hold on Tight?
Why Is Cencora (COR) Down 2.8% Since Last Earnings Report?
Icon PLC (ICLR) Up 2.3% Since Last Earnings Report: Can It Continue?
Other News for ELV
Health insurers unveil 2025 Medicare Advantage plans, Reuters reports
Elevance Health Responds to Communities Affected by Hurricane Helene
Barclays sees margin benefits from Humana, CVS Medicare Advantage exits
ELV September 2025 Options Begin Trading
Humana: A Beaten-Down Health Care Stock to Re-Emerge as Inflation Fades